down arrow

Terns Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8808811074
USD
27.13
1.34 (5.2%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

26.5328.13

52 Week

1.8629.51
Valuation
Technical
Day's Volume

CASH

779.81 k

Shareholding (Mar 2025)

FII

14.21%

Held by 75 FIIs

DII

40.93%

Held by 34 DIIs

Promoter

21.89%

How big is Terns Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Terns Pharmaceuticals, Inc. has a market capitalization of 340.62 million and reported net sales of 0.00 million with a net profit of -90.40 million for the latest four quarters. Shareholder's funds are at 345.87 million and total assets at 363.93 million as of Dec 24.

As of Jun 18, Terns Pharmaceuticals, Inc. has a market capitalization of 340.62 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -90.40 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 345.87 million and Total Assets at 363.93 million.

Read More

What does Terns Pharmaceuticals, Inc. do?

22-Jun-2025

Terns Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net loss of $24 million and a market cap of $340.62 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -27.72%.

Overview: <BR>Terns Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -24 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 340.62 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.02 <BR>Return on Equity: -27.72% <BR>Price to Book: 1.04<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Terns Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of March 27, 2023, Terns Pharmaceuticals, Inc. is considered overvalued with a valuation downgrade to "does not qualify," reflected by a negative P/E ratio of -3.7684, a significant decline in stock performance, and concerning profitability metrics, indicating poor investment appeal at its current price of $3.68.

As of 27 March 2023, the valuation grade for Terns Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company appears to be overvalued given its current metrics, with a Price to Book Value of 0.99 and an EV to EBIT of 0.10, suggesting that the market may not be accurately reflecting the company's underlying value. Additionally, the Return on Capital Employed (ROCE) is exceptionally high at 1332.80%, but the Return on Equity (ROE) is negative at -27.72%, indicating potential issues with profitability.<BR><BR>In comparison to its peers, Terns Pharmaceuticals has a P/E ratio of -3.7684, while Scholar Rock Holding Corp. and Edgewise Therapeutics, Inc. have P/E ratios of -11.1959 and -10.4346, respectively, both indicating a challenging environment for valuation. The recent stock performance shows a decline of 49.1% over the past year compared to a 10.26% increase in the S&P 500, reinforcing the notion that Terns Pharmaceuticals is struggling relative to broader market trends. Overall, the combination of negative ratios and poor stock performance suggests that the company is overvalued at its current price of $3.68.

Read More

Is Terns Pharmaceuticals, Inc. technically bullish or bearish?

30-Sep-2025

As of September 26, 2025, Terns Pharmaceuticals, Inc. shows a bullish technical trend with positive momentum indicators, although caution is advised due to mixed longer-term signals and underperformance over the past year compared to the S&P 500.

As of 26 September 2025, the technical trend for Terns Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages also support a bullish stance. However, the monthly KST is bearish, and the monthly OBV is mildly bearish, suggesting some caution. <BR><BR>In terms of performance, Terns Pharmaceuticals has outperformed the S&P 500 over the past week and month, with returns of 1.46% and 5.38% compared to -0.31% and 2.75% for the index, respectively. However, over the past year, the stock has underperformed the S&P 500, with a return of -13.67% against 15.64%. Overall, the current technical stance is bullish, with moderate strength driven by positive indicators, despite some mixed signals in longer-term metrics.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 637 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.03

stock-summary
Return on Equity

-30.06%

stock-summary
Price to Book

2.09

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-24 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
264.65%
0%
264.65%
6 Months
676.25%
0%
676.25%
1 Year
326.57%
0%
326.57%
2 Years
419.73%
0%
419.73%
3 Years
323.24%
0%
323.24%
4 Years
271.14%
0%
271.14%
5 Years
0%
0%
0.0%

Terns Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Terns Pharmaceuticals, Inc. technically bullish or bearish?

As of 26 September 2025, the technical trend for Terns Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages also support a bullish stance. However, the monthly KST is bearish, and the monthly OBV is mildly bearish, suggesting some caution. In terms of performance, Terns Pharmaceuticals has outperformed the S&P 500 over the past week and month, with returns of 1.46% and 5.38% compared to -0.31% and 2.75% for the index, respectively. However, over the past year, the stock has underperformed the S&P 500, with a return of -13.67% against 15.64%. Overall, the current technical stance is bullish, with moderate strength driven by positive indicators, despite some mixed signals in longer-term metrics....

Read More

Is Terns Pharmaceuticals, Inc. technically bullish or bearish?

As of 26 September 2025, the technical trend for Terns Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and Bollinger Bands are also indicating a bullish stance on both weekly and monthly time frames. Daily moving averages support a bullish outlook. However, the monthly KST is bearish, and the monthly OBV is mildly bearish, which suggests some caution. The stock has outperformed the S&P 500 over the past week and month, with returns of 1.46% and 5.38% respectively, while the S&P 500 saw declines and modest gains. Overall, the current technical stance is bullish, with moderate strength....

Read More

Is Terns Pharmaceuticals, Inc. technically bullish or bearish?

As of 26 September 2025, the technical trend for Terns Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. The daily moving averages also support a bullish stance. However, the monthly KST is bearish, and the monthly OBV is mildly bearish, which suggests some caution. In terms of performance, Terns Pharmaceuticals has outperformed the S&P 500 over the past week and month, with returns of 1.46% and 5.38% respectively, while the S&P 500 recorded -0.31% and 2.75%. Year-to-date, Terns shows a strong return of 37.91% compared to the S&P's 12.96%, although it has underperformed over the past year. Overall, the current technical stance is bullish with moderate strength....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
-210.58%
EBIT to Interest (avg)
-73.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.99
EV to EBIT
0.10
EV to EBITDA
0.10
EV to Capital Employed
1.37
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1332.80%
ROE (Latest)
-27.72%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bullish
Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 40 Schemes (22.96%)

Foreign Institutions

Held by 75 Foreign Institutions (14.21%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -6.17% vs -26.82% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-27.30",
          "val2": "-25.30",
          "chgp": "-7.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.10",
          "val2": "-22.70",
          "chgp": "-6.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 1.44% vs -49.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-101.00",
          "val2": "-101.70",
          "chgp": "0.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-88.90",
          "val2": "-90.20",
          "chgp": "1.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-27.30
-25.30
-7.91%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-24.10
-22.70
-6.17%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -6.17% vs -26.82% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-101.00
-101.70
0.69%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-88.90
-90.20
1.44%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 1.44% vs -49.59% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Terns Pharmaceuticals, Inc. stock-summary
stock-summary
Terns Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."